AstraZeneca drug combo gets US nod to treat a type of prostate cancer

[June 01, 2023]  (Reuters) - AstraZeneca said on Thursday that a combination of its cancer drug Lynparza and abiraterone has been approved in the United States for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

The company said the combination treatment reduced the risk of disease progression or death by 76% compared with usage of abiraterone alone.

(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Savio D'Souza)

A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble/File Photo

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.